Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: jbe who wrote (7614)	4/14/1998 5:34:00 PM
From: Jenna	Respond to of 120523

IMPORTANT MESSAGE: ELN very important player in medical ethical drugs group. Elan has the niche on epilepsy drugs. I have the report date as April 23, but it is in YHOO as reporting tomorrow. I will check and report back. Three new epilepsy drugs from Elan are expected to generate nearly $100 million in sales by next year. Diastat, for seizure control, was launched in the U.S. in the Fall. Another Zonisamide is awaiting final approval by the Food & Drug Administration. the third Carbatrol just received approval and is being readied for launch. Adding to this growth potential, Elan acquired Mysoline, an anticonvulsant drug for epilepsy, from American Home Products' Wyeth-Ayerst Laboratories last month. The drug's yearly sales average 15 million. But analysts believe Elan can increase these sales to $20 million in 1999. Research and devlopment in the neurosciences has been underserved. Last year Elan spent $100 million on research and development. Its research department includes 500 people. Its labs spans the globe -- from Switzerland to Israel to America. Company markets 20 products in 44 nations..approval is sought for 12 products. It's niche is epilepsy.. Recently, the company signed two agreemtns or reformulate drugs with Novartis Pharmaceuticals Corp. and solvay Pharmacueticals. I've come across this company in Israel where it is extremely respected and is in the same league as JNJ, GLaxo Wellcome and WLA, and ABT. I've also got a cousin in Israel whose unbelievably debilitating seizures have been totally controlled by Diastat which has been available in Israel for a few years now. As far as the chart goes.. the stochastic show an OVERSOLD picture. resistance is at 68.. and should break through 69 which is the 52 week high on a good report.